0001578563-16-000018.txt : 20160913 0001578563-16-000018.hdr.sgml : 20160913 20160913121320 ACCESSION NUMBER: 0001578563-16-000018 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160913 DATE AS OF CHANGE: 20160913 EFFECTIVENESS DATE: 20160913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-270499 FILM NUMBER: 161882393 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 212-554-4366 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 D 1 primary_doc.xml X0707 D LIVE 0001651407 Checkpoint Therapeutics, Inc. 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY NEW YORK 10014 212-554-4366 DELAWARE None None Corporation true 2014 James F. Oliviero, III c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Executive Officer Michael S. Weiss c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director David J. Horin c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Executive Officer Lindsay A. Rosenwald c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Neil Herskowitz c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Barry Salzman c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Scott Boilen c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Biotechnology Decline to Disclose 06b false 2015-09-30 false true true false 0 National Securities Corporation 7569 National Securities Corporation 7569 410 Park Avenue 14th Floor New York NY NEW YORK 10022 All States false 62500000 57817000 4683000 false 559 5781700 0 In addition to the cash commission above, Issuer also issued warrants to purchase a number of shares of the Issuer's Common Stock equal to 10% of the aggregate amount of shares into which the Notes sold in the offering eventually are convertible. 0 Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering. false Checkpoint Therapeutics, Inc. /s/ James F. Oliviero, III James F. Oliviero, III President and Chief Executive Officer 2016-09-08